予測・発症前検査の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Predictive Presymptomatic Testing Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-16434 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、105ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、予測・発症前検査の世界市場を広く調査・分析し、今後の市場展望をまとめております。予測・発症前検査の種類別市場規模（分子検査、細胞形成検査、生化学検査）、用途別市場規模（乳癌・卵巣癌、結腸直腸癌、アルツハイマー病、多発性内分泌腫瘍2型、ヘモクロマトーシス）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：23andMe, Inc.、Cepheid (Danaher)、Biocartis SA、Abbott Laboratories、Celera Corporation (Quest Diagnostics)、Bayer HealthCare AG、EKF Diagnostics Holdings plc、bioMerieux S.A.、BioHelix Corporation、Daan Diagnostics Ltd. ・地域別グローバル市場分析 2015年-2020年 ・予測・発症前検査の北米市場（アメリカ、カナダ、メキシコ） ・予測・発症前検査のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・予測・発症前検査のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・予測・発症前検査の南米市場（ブラジル、アルゼンチン） ・予測・発症前検査の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：分子検査、細胞形成検査、生化学検査 ・用途別分析：乳癌・卵巣癌、結腸直腸癌、アルツハイマー病、多発性内分泌腫瘍2型、ヘモクロマトーシス ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Predictive Presymptomatic Testing market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Predictive Presymptomatic Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Predictive Presymptomatic Testing market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Predictive Presymptomatic Testing market has been segmented into:
Molecular Testing
Cytogenic Testing
Biochemical Testing

By Application, Predictive Presymptomatic Testing has been segmented into:
Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer’s Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Predictive Presymptomatic Testing market presented in the report. This section sheds light on the sales growth of different regional and country-level Predictive Presymptomatic Testing markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Predictive Presymptomatic Testing market.

The report offers in-depth assessment of the growth and other aspects of the Predictive Presymptomatic Testing market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Predictive Presymptomatic Testing Market Share Analysis
Predictive Presymptomatic Testing competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Predictive Presymptomatic Testing sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Predictive Presymptomatic Testing sales, revenue and market share for each player covered in this report.

The major players covered in Predictive Presymptomatic Testing are:
23andMe, Inc.
Cepheid (Danaher)
Biocartis SA
Abbott Laboratories
Celera Corporation (Quest Diagnostics)
Bayer HealthCare AG
EKF Diagnostics Holdings plc
bioMerieux S.A.
BioHelix Corporation
Daan Diagnostics Ltd.

レポート目次

---

Table of Contents

1 Predictive Presymptomatic Testing Market Overview
1.1 Product Overview and Scope of Predictive Presymptomatic Testing
1.2 Classification of Predictive Presymptomatic Testing by Type
1.2.1 Global Predictive Presymptomatic Testing Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Predictive Presymptomatic Testing Revenue Market Share by Type in 2019
1.2.3 Molecular Testing
1.2.4 Cytogenic Testing
1.2.5 Biochemical Testing
1.3 Global Predictive Presymptomatic Testing Market by Application
1.3.1 Overview: Global Predictive Presymptomatic Testing Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Breast and Ovarian Cancer
1.3.3 Colorectal Cancer
1.3.4 Alzheimer’s Disease
1.3.5 Multiple Endocrine Neoplasia Type 2
1.3.6 Haemochromatosis
1.4 Global Predictive Presymptomatic Testing Market by Regions
1.4.1 Global Predictive Presymptomatic Testing Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Predictive Presymptomatic Testing (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Predictive Presymptomatic Testing Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Predictive Presymptomatic Testing Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Predictive Presymptomatic Testing Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Predictive Presymptomatic Testing Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Predictive Presymptomatic Testing Status and Prospect (2015-2025)
2 Company Profiles
2.1 23andMe, Inc.
2.1.1 23andMe, Inc. Details
2.1.2 23andMe, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 23andMe, Inc. SWOT Analysis
2.1.4 23andMe, Inc. Product and Services
2.1.5 23andMe, Inc. Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.2 Cepheid (Danaher)
2.2.1 Cepheid (Danaher) Details
2.2.2 Cepheid (Danaher) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Cepheid (Danaher) SWOT Analysis
2.2.4 Cepheid (Danaher) Product and Services
2.2.5 Cepheid (Danaher) Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.3 Biocartis SA
2.3.1 Biocartis SA Details
2.3.2 Biocartis SA Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Biocartis SA SWOT Analysis
2.3.4 Biocartis SA Product and Services
2.3.5 Biocartis SA Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.4 Abbott Laboratories
2.4.1 Abbott Laboratories Details
2.4.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Abbott Laboratories SWOT Analysis
2.4.4 Abbott Laboratories Product and Services
2.4.5 Abbott Laboratories Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.5 Celera Corporation (Quest Diagnostics)
2.5.1 Celera Corporation (Quest Diagnostics) Details
2.5.2 Celera Corporation (Quest Diagnostics) Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Celera Corporation (Quest Diagnostics) SWOT Analysis
2.5.4 Celera Corporation (Quest Diagnostics) Product and Services
2.5.5 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bayer HealthCare AG
2.6.1 Bayer HealthCare AG Details
2.6.2 Bayer HealthCare AG Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bayer HealthCare AG SWOT Analysis
2.6.4 Bayer HealthCare AG Product and Services
2.6.5 Bayer HealthCare AG Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.7 EKF Diagnostics Holdings plc
2.7.1 EKF Diagnostics Holdings plc Details
2.7.2 EKF Diagnostics Holdings plc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 EKF Diagnostics Holdings plc SWOT Analysis
2.7.4 EKF Diagnostics Holdings plc Product and Services
2.7.5 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.8 bioMerieux S.A.
2.8.1 bioMerieux S.A. Details
2.8.2 bioMerieux S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 bioMerieux S.A. SWOT Analysis
2.8.4 bioMerieux S.A. Product and Services
2.8.5 bioMerieux S.A. Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.9 BioHelix Corporation
2.9.1 BioHelix Corporation Details
2.9.2 BioHelix Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 BioHelix Corporation SWOT Analysis
2.9.4 BioHelix Corporation Product and Services
2.9.5 BioHelix Corporation Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
2.10 Daan Diagnostics Ltd.
2.10.1 Daan Diagnostics Ltd. Details
2.10.2 Daan Diagnostics Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Daan Diagnostics Ltd. SWOT Analysis
2.10.4 Daan Diagnostics Ltd. Product and Services
2.10.5 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Predictive Presymptomatic Testing Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Predictive Presymptomatic Testing Players Market Share
3.2.2 Top 10 Predictive Presymptomatic Testing Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Predictive Presymptomatic Testing Revenue and Market Share by Regions
4.2 North America Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
4.3 Europe Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
4.5 South America Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
5 North America Predictive Presymptomatic Testing Revenue by Countries
5.1 North America Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
5.2 USA Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
5.3 Canada Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
5.4 Mexico Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
6 Europe Predictive Presymptomatic Testing Revenue by Countries
6.1 Europe Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
6.2 Germany Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
6.3 UK Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
6.4 France Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
6.5 Russia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
6.6 Italy Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Predictive Presymptomatic Testing Revenue by Countries
7.1 Asia-Pacific Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
7.2 China Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
7.3 Japan Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
7.4 Korea Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
7.5 India Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
8 South America Predictive Presymptomatic Testing Revenue by Countries
8.1 South America Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
8.2 Brazil Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
8.3 Argentina Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Predictive Presymptomatic Testing by Countries
9.1 Middle East & Africa Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
9.2 Saudi Arabia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
9.3 UAE Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
9.4 Egypt Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
9.5 South Africa Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Predictive Presymptomatic Testing Revenue and Market Share by Type (2015-2020)
10.2 Global Predictive Presymptomatic Testing Market Forecast by Type (2019-2024)
10.3 Molecular Testing Revenue Growth Rate (2015-2025)
10.4 Cytogenic Testing Revenue Growth Rate (2015-2025)
10.5 Biochemical Testing Revenue Growth Rate (2015-2025)
11 Global Predictive Presymptomatic Testing Market Segment by Application
11.1 Global Predictive Presymptomatic Testing Revenue Market Share by Application (2015-2020)
11.2 Predictive Presymptomatic Testing Market Forecast by Application (2019-2024)
11.3 Breast and Ovarian Cancer Revenue Growth (2015-2020)
11.4 Colorectal Cancer Revenue Growth (2015-2020)
11.5 Alzheimer’s Disease Revenue Growth (2015-2020)
11.6 Multiple Endocrine Neoplasia Type 2 Revenue Growth (2015-2020)
11.7 Haemochromatosis Revenue Growth (2015-2020)
12 Global Predictive Presymptomatic Testing Market Size Forecast (2021-2025)
12.1 Global Predictive Presymptomatic Testing Market Size Forecast (2021-2025)
12.2 Global Predictive Presymptomatic Testing Market Forecast by Regions (2021-2025)
12.3 North America Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
12.4 Europe Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
12.6 South America Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Predictive Presymptomatic Testing Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Predictive Presymptomatic Testing by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Predictive Presymptomatic Testing Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Predictive Presymptomatic Testing Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. 23andMe, Inc. Corporate Information, Location and Competitors
Table 6. 23andMe, Inc. Predictive Presymptomatic Testing Major Business
Table 7. 23andMe, Inc. Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 8. 23andMe, Inc. SWOT Analysis
Table 9. 23andMe, Inc. Predictive Presymptomatic Testing Product and Solutions
Table 10. 23andMe, Inc. Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Cepheid (Danaher) Corporate Information, Location and Competitors
Table 12. Cepheid (Danaher) Predictive Presymptomatic Testing Major Business
Table 13. Cepheid (Danaher) Predictive Presymptomatic Testing Total Revenue (USD Million) (2018-2019)
Table 14. Cepheid (Danaher) SWOT Analysis
Table 15. Cepheid (Danaher) Predictive Presymptomatic Testing Product and Solutions
Table 16. Cepheid (Danaher) Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Biocartis SA Corporate Information, Location and Competitors
Table 18. Biocartis SA Predictive Presymptomatic Testing Major Business
Table 19. Biocartis SA Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 20. Biocartis SA SWOT Analysis
Table 21. Biocartis SA Predictive Presymptomatic Testing Product and Solutions
Table 22. Biocartis SA Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Abbott Laboratories Corporate Information, Location and Competitors
Table 24. Abbott Laboratories Predictive Presymptomatic Testing Major Business
Table 25. Abbott Laboratories Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 26. Abbott Laboratories SWOT Analysis
Table 27. Abbott Laboratories Predictive Presymptomatic Testing Product and Solutions
Table 28. Abbott Laboratories Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Celera Corporation (Quest Diagnostics) Corporate Information, Location and Competitors
Table 30. Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Major Business
Table 31. Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 32. Celera Corporation (Quest Diagnostics) SWOT Analysis
Table 33. Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Product and Solutions
Table 34. Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Bayer HealthCare AG Corporate Information, Location and Competitors
Table 36. Bayer HealthCare AG Predictive Presymptomatic Testing Major Business
Table 37. Bayer HealthCare AG Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 38. Bayer HealthCare AG SWOT Analysis
Table 39. Bayer HealthCare AG Predictive Presymptomatic Testing Product and Solutions
Table 40. Bayer HealthCare AG Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. EKF Diagnostics Holdings plc Corporate Information, Location and Competitors
Table 42. EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Major Business
Table 43. EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 44. EKF Diagnostics Holdings plc SWOT Analysis
Table 45. EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Product and Solutions
Table 46. EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. bioMerieux S.A. Corporate Information, Location and Competitors
Table 48. bioMerieux S.A. Predictive Presymptomatic Testing Major Business
Table 49. bioMerieux S.A. Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 50. bioMerieux S.A. SWOT Analysis
Table 51. bioMerieux S.A. Predictive Presymptomatic Testing Product and Solutions
Table 52. bioMerieux S.A. Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. BioHelix Corporation Corporate Information, Location and Competitors
Table 54. BioHelix Corporation Predictive Presymptomatic Testing Major Business
Table 55. BioHelix Corporation Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 56. BioHelix Corporation SWOT Analysis
Table 57. BioHelix Corporation Predictive Presymptomatic Testing Product and Solutions
Table 58. BioHelix Corporation Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Daan Diagnostics Ltd. Corporate Information, Location and Competitors
Table 60. Daan Diagnostics Ltd. Predictive Presymptomatic Testing Major Business
Table 61. Daan Diagnostics Ltd. Predictive Presymptomatic Testing Total Revenue (USD Million) (2017-2018)
Table 62. Daan Diagnostics Ltd. SWOT Analysis
Table 63. Daan Diagnostics Ltd. Predictive Presymptomatic Testing Product and Solutions
Table 64. Daan Diagnostics Ltd. Predictive Presymptomatic Testing Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Predictive Presymptomatic Testing Revenue (Million USD) by Players (2015-2020)
Table 66. Global Predictive Presymptomatic Testing Revenue Share by Players (2015-2020)
Table 67. Global Predictive Presymptomatic Testing Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Predictive Presymptomatic Testing Revenue Market Share by Regions (2015-2020)
Table 69. North America Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
Table 70. North America Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Table 71. Europe Predictive Presymptomatic Testing Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Predictive Presymptomatic Testing Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Predictive Presymptomatic Testing Revenue by Countries (2015-2020)
Table 74. South America Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Predictive Presymptomatic Testing Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Table 77. Global Predictive Presymptomatic Testing Revenue (Million USD) by Type (2015-2020)
Table 78. Global Predictive Presymptomatic Testing Revenue Share by Type (2015-2020)
Table 79. Global Predictive Presymptomatic Testing Revenue Forecast by Type (2021-2025)
Table 80. Global Predictive Presymptomatic Testing Revenue by Application (2015-2020)
Table 81. Global Predictive Presymptomatic Testing Revenue Share by Application (2015-2020)
Table 82. Global Predictive Presymptomatic Testing Revenue Forecast by Application (2021-2025)
Table 83. Global Predictive Presymptomatic Testing Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Predictive Presymptomatic Testing Picture
Figure 2. Global Predictive Presymptomatic Testing Revenue Market Share by Type in 2019
Figure 3. Molecular Testing Picture
Figure 4. Cytogenic Testing Picture
Figure 5. Biochemical Testing Picture
Figure 6. Predictive Presymptomatic Testing Revenue Market Share by Application in 2019
Figure 7. Breast and Ovarian Cancer Picture
Figure 8. Colorectal Cancer Picture
Figure 9. Alzheimer's Disease Picture
Figure 10. Multiple Endocrine Neoplasia Type 2 Picture
Figure 11. Haemochromatosis Picture
Figure 12. Global Predictive Presymptomatic Testing Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Predictive Presymptomatic Testing Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Predictive Presymptomatic Testing Revenue Market Share in 2019
Figure 21. Global Top 10 Players Predictive Presymptomatic Testing Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Predictive Presymptomatic Testing Revenue Market Share by Regions (2015-2020)
Figure 25. Global Predictive Presymptomatic Testing Revenue Market Share by Regions in 2018
Figure 26. North America Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 27. Europe Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 29. South America Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 31. North America Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Figure 32. North America Predictive Presymptomatic Testing Revenue Market Share by Countries in 2019
Figure 33. USA Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 34. Canada Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 36. Europe Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Predictive Presymptomatic Testing Revenue Market Share by Countries in 2019
Figure 38. Germany Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 39. UK Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 40. France Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 41. Russia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 42. Italy Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Predictive Presymptomatic Testing Revenue Market Share by Countries in 2019
Figure 45. China Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 46. Japan Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 47. Korea Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 48. India Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 50. South America Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Figure 51. South America Predictive Presymptomatic Testing Revenue Market Share by Countries in 2019
Figure 52. Brazil Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Predictive Presymptomatic Testing Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Predictive Presymptomatic Testing Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 57. UAE Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Predictive Presymptomatic Testing Revenue and Growth Rate (2015-2020)
Figure 60. Global Predictive Presymptomatic Testing Revenue Share by Type (2015-2020)
Figure 61. Global Predictive Presymptomatic Testing Revenue Share by Type in 2019
Figure 62. Global Predictive Presymptomatic Testing Market Share Forecast by Type (2021-2025)
Figure 63. Global Molecular Testing Revenue Growth Rate (2015-2020)
Figure 64. Global Cytogenic Testing Revenue Growth Rate (2015-2020)
Figure 65. Global Biochemical Testing Revenue Growth Rate (2015-2020)
Figure 66. Global Predictive Presymptomatic Testing Revenue Share by Application (2015-2020)
Figure 67. Global Predictive Presymptomatic Testing Revenue Share by Application in 2019
Figure 68. Global Predictive Presymptomatic Testing Market Share Forecast by Application (2021-2025)
Figure 69. Global Breast and Ovarian Cancer Revenue Growth Rate (2015-2020)
Figure 70. Global Colorectal Cancer Revenue Growth Rate (2015-2020)
Figure 71. Global Alzheimer's Disease Revenue Growth Rate (2015-2020)
Figure 72. Global Multiple Endocrine Neoplasia Type 2 Revenue Growth Rate (2015-2020)
Figure 73. Global Haemochromatosis Revenue Growth Rate (2015-2020)
Figure 74. Global Predictive Presymptomatic Testing Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Predictive Presymptomatic Testing Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Predictive Presymptomatic Testing Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
Figure 78. Europe Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
Figure 80. South America Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Predictive Presymptomatic Testing Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---